Celgene shows CAR-T confidence with $1bn Juno investment
This article was originally published in Scrip
Executive Summary
Celgene is known as a creative yet disciplined dealmaker, so the fact that the big biotech company is investing $1bn up front under a 10-year agreement with Juno Therapeutics shows that Celgene sees a lot of value in the early-stage, closely-watched field of chimeric antigen T-cell receptor (CAR-T) therapies.
You may also be interested in...
Celgene Seeks CAR-T Leadership, Hematology Diversification With Juno Buy
Celgene will pay $9bn to buy the 90.3% of Juno that it doesn't already own, seeking to not only become a leader in the CAR-T field, but to increase its leadership in non-Hodgkin lymphoma, multiple myeloma, other hematological malignancies.
Celgene's CAR-T Leadership Goals Advance At ASH 2017
Celgene's partnership strategy paid off at ASH with positive results for two CAR-T therapies in development with bluebird bio and Juno. The company is pursuing first- and best-in-class opportunities with the goal of becoming a leader in the CAR-T field.
Celgene's CAR-T Leadership Goals Advance At ASH 2017
Celgene's partnership strategy paid off at ASH with positive results for two CAR-T therapies in development with bluebird bio and Juno. The company is pursuing first- and best-in-class opportunities with the goal of becoming a leader in the CAR-T field.